Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07681375 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor
A Phase 1 study, sponsored by DexCom.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT07681375: Active Phase 1 study, sponsored by DexCom.
NCT07681375 is a Phase 1 study that is active but no longer recruiting, run by DexCom. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07681375, a Phase 1 study, is active but no longer recruiting, sponsored by DexCom.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
To evaluate the feasibility of the DexBasal Study System
Primary Outcome
Subject safety measured by the number of Severe Adverse Events (SAEs)
Interventions
- DRUG Basal insulin
- DEVICE Dexcom Continuous Glucose Monitoring (CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 1 |
What the registry record for NCT07681375 still lists
NCT07681375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Basal insulin is the first listed.
NCT07681375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07681375 about?
NCT07681375 is a clinical study titled "Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor". To evaluate the feasibility of the DexBasal Study System
What is the current status of trial NCT07681375?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-04-11. Estimated completion is 2027-01-15.
What interventions are being tested in trial NCT07681375?
The interventions under investigation include: Basal insulin (DRUG), Dexcom Continuous Glucose Monitoring (CGM) (DEVICE).
Who is sponsoring clinical trial NCT07681375?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07681375's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI